Media and Communications

News

NA

Monday, July 21, 2014
Teva Completes Acquisition of Labrys: Opens Door to a Strong and Novel Migraine Prevention and Treatment Franchise within its CNS Portfolio

JERUSALEM--(BUSINESS WIRE)--Jul. 21, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced the successful completion of the acquisition of Labrys. The acquisition of Labrys brings to Teva LBR-101, a fully humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP), which is currently in Phase IIb clinical trials for prevention of chronic and episodic migraine. Teva’s acquisition of LBR-101 complements the recent acquisition of ZECUITY®, a novel iontophoretic patch that delivers sumatript Read More »

Wednesday, July 16, 2014
Leading U.S. Proxy Advisory Firm Supports Teva Nominees and Other Shareholders’ Meeting Proposals

JERUSALEM--(BUSINESS WIRE)--Jul. 16, 2014-- Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) reported today that ISS Proxy Advisory Services, the leading U.S. independent proxy advisory firm, recommended that shareholders vote in favor of all Teva nominees for director (Messrs. Jean-Michel Halfon, Joseph (Yossi) Nitzani, Dan Propper and Ory Slonim) and for each of the other proposals on the agenda for consideration at the Company's upcoming annual general meeting of shareholders. ISS provides voting analysis on more than 20,00 Read More »

Monday, July 14, 2014
Teva Announces FDA Acceptance of NDA Filing for Investigational Short-Acting Beta-Agonist (SABA) Inhaler (Albuterol MDPI)

First Breath-Actuated Dry-Powder SABA Inhaler to be Accepted by FDA for Review JERUSALEM--(BUSINESS WIRE)--Jul. 14, 2014-- Teva Pharmaceuticals Industries Ltd., (NYSE:TEVA) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s new drug application (NDA) for albuterol multi-dose dry-powder inhaler (MDPI), an investigational breath-actuated dry-powder inhaler for the treatment or prevention of bronchospasm in patients 12 years of age and older with reversible obstructive airway di Read More »

Thursday, July 03, 2014
ADDING MULTIMEDIA Teva Files Citizen Petition with the U.S. Food and Drug Administration (FDA) Regarding the Complexity of COPAXONE® (glatiramer acetate) Following the Agency’s Guidance

 View COPAXONE® Citizen PetitionTeva includes new gene expression data in its CP, supporting the need for active ingredient sameness of any purported generic version of COPAXONE® JERUSALEM--(BUSINESS WIRE)--Jul. 3, 2014-- Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that the Company has filed a citizen petition (CP) regarding the approvability of purported generic versions of COPAXONE®. Teva submitted this CP according to the FDA’s procedural guidance and in accordance with the Agency’s desire to facilitate public review and comment regarding new scientific data on gene Read More »

Tuesday, June 17, 2014
Teva Reaches Settlements In NUVIGIL® Patent Case

JERUSALEM--(BUSINESS WIRE)--Jun. 17, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that it has reached settlements with Sandoz, Actavis, Lupin and Apotex with respect to U.S. Patent 7,132,570 (the “570 patent”) for Teva’s wakefulness product, NUVIGIL® (armodafinil) tablets. These settlements dismiss a pending appeal with the United States Court of Appeals for the Federal Circuit of a trial court decision that found the ‘570 patent to be valid and infringed. Teva has reached settlements with each of these com Read More »

Monday, June 09, 2014
FDA Approves Expanded Label for AZILECT® for Treatment Across All Stages of Parkinson’s Disease

JERUSALEM--(BUSINESS WIRE)--Jun. 9, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced the U.S. Food and Drug Administration (FDA) has expanded the indication for AZILECT® (rasagiline tablets) from monotherapy and adjunct to levodopa (LD) to now include adjunct to dopamine agonists (DAs). The new indication reflects that AZILECT® can be used alone or in combination with other Parkinson’s disease (PD) medications. The approval reinforces the growing clinical evidence demonstrating the benefit of AZILECT® across all Read More »

Thursday, June 05, 2014
Teva to Present at the Goldman Sachs 35th Annual Global Healthcare Conference

JERUSALEM--(BUSINESS WIRE)--Jun. 5, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will host a live audio webcast at the Goldman Sachs 35th Annual Global Healthcare Conference. Eyal Desheh, EVP & CFO will present on Tuesday, June 10, 2014 at 2 PM PT. What:   Teva Presentation at the Goldman Sachs 35th Annual Global Healthcare Conference   Read More »

Monday, June 02, 2014
Teva Announces New Organizational Structure and Senior Leadership Changes, Enabling the Global Integration of the Company and Positioning It for Short- and Long-Term Value Creation

APPOINTS SIGURDUR OLAFSSON AS PRESIDENT AND CEO OF NEWLY ESTABLISHED GLOBAL GENERIC MEDICINES GROUP New, fully integrated Global Generic Medicines Group will be responsible for all global commercial activity Newly formed Corporate Development, Strategy and Innovation Group, with broader scope Establishes Global Corporate Marketing Excellence and Communications Group Appoints new Global Head of Quality Lean, focused, integrative s Read More »

Thursday, May 29, 2014
Teva to Present at the Jefferies 2014 Global Healthcare Conference

JERUSALEM--(BUSINESS WIRE)--May 29, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will host a live audio webcast at the Jefferies 2014 Global Healthcare Conference. Jon Congleton, SVP & Head of Global CNS will present on Tuesday, June 3, 2014 at 9:00 AM ET. What: Teva Presentation at the Jefferies 2014 Global Healthcare Conference Who: Jon Congleton, SVP & Head of Global CNS, Teva Pharmaceutical Industries Ltd. When: Tuesday, June 3, 2014 Where: www.tevapharm.com Read More »

Tuesday, May 27, 2014
Teva Announces Favorable European Patent Office Ruling in COPAXONE® Patent Proceeding

JERUSALEM--(BUSINESS WIRE)--May 27, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that the European Patent Office issued a decision in favor of Teva in a patent opposition proceeding filed by Synthon BV, Mylan and an unidentified third party. On September 6, 2012, the three opponents commenced an opposition proceeding against European Patent EP 2 177 528, a patent for COPAXONE® (glatiramer acetate injection) expiring September 9, 2025. In today's hearing, the European Patent Office specifically determined that claim Read More »

​​​